Identification and validation of targets of swertiamarin on idiopathic pulmonary fibrosis through bioinformatics and molecular docking-based approach

BACKGROUND: Swertiamarin is the main hepatoprotective component of Swertiapatens and has anti-inflammatory and antioxidation effects. Our previous study showed that it was a potent inhibitor of idiopathic pulmonary fibrosis (IPF) and can regulate the expressions of α-smooth muscle actin (α-SMA) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Chang, Jun, Zou, Shaoqing, Xiao, Yiwen, Zhu, Du
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557187/
https://www.ncbi.nlm.nih.gov/pubmed/37798725
http://dx.doi.org/10.1186/s12906-023-04171-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557187/
https://www.ncbi.nlm.nih.gov/pubmed/37798725
http://dx.doi.org/10.1186/s12906-023-04171-w

Ejemplares similares